Pharmaceutical Executive September 25, 2025
Aside from pricing changes, the impacts that MFN could have on the US market could have global reverberations.
Peter Rubin, executive director of No Patient Left Behind, spoke with Pharmaceutical Executive about President Trump’s Most-Favored Nation (MFN) order and the widespread impact it could have on the industry. While the order seeks to reduce drug costs in the United States by enforcing a rule based on foreign prices, it’s likely that this rule could force pharma companies, large and small, to adjust the way they approach innovation. According to Rubin, the ruling is likely to impact more than just pricing. He also believes that it will be hard to even find a fair price for the drugs using the MFN...
Today's Sponsors
Today's Sponsor